Travere Therapeutics, Inc. today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics (TVTX) on Wednesday announced the pricing of its underwritten offering of $475M aggregate principal amount of 0.50% convertible senior notes due 2032. The sale of the notes is ...

Quanterix Corporation , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO" ...

New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...

Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE)-- Ligand Pharmaceuticals ...

Researchers report the impact of sparsentan vs irbesartan on proteinuria in patients with focal segmental glomerulosclerosis.

MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales ...

Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from ...